Recent Advances in Multiple Myeloma: Highlights from the IMS 2022 Meeting and Beyond

home / around-the-practice / recent-advances-in-multiple-myeloma-highlights-from-the-ims-2022-meeting-and-beyond

A panel of experts in multiple myeloma discusses recent data updates from IMS 2022 [International Myeloma Society Annual Meeting] and how it influences treatment strategies in clinical practice.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

EP. 1: Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
September 15th 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

EP. 2: Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
September 15th 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

EP. 3: Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
September 22nd 2022

Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.

Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM

EP. 4: Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
September 22nd 2022

Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.

Treating Patients with High-Risk NDMM

EP. 5: Treating Patients with High-Risk NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
September 29th 2022

The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.

Factors to Consider for Frontline Treatment of Transplant-Ineligible MM

EP. 6: Factors to Consider for Frontline Treatment of Transplant-Ineligible MM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
September 29th 2022

Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.

Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials

EP. 7: Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 6th 2022

Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.

Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study

EP. 8: Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 6th 2022

Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.

Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM

EP. 9: Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 12th 2022

Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.

Maintenance Therapy in Transplant-Ineligible NDMM

EP. 10: Maintenance Therapy in Transplant-Ineligible NDMM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 12th 2022

Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.

Available Treatment Options for Relapsed/Refractory Multiple Myeloma

EP. 11: Available Treatment Options for Relapsed/Refractory Multiple Myeloma

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 19th 2022

Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.

Bispecific Antibodies in the Treatment of R/R MM

EP. 12: Bispecific Antibodies in the Treatment of R/R MM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 19th 2022

An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.

CAR-T Therapy in R/R MM Treatment

EP. 13: CAR-T Therapy in R/R MM Treatment

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 26th 2022

Key opinion leaders compare the overall benefits of CAR-T therapy and share some advice for managing the toxicities of CAR-T therapy as a patient transitions back to their local doctor.

Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy

EP. 14: Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
October 26th 2022

Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.

Sequencing Therapies in Patients with R/R MM

EP. 15: Sequencing Therapies in Patients with R/R MM

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
November 2nd 2022

Drs Cowan and Anderson review whether older agents such as isa-based regimens still have a place in R/R MM treatment after the introduction of bispecific agents and CAR-T therapy.

Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022

EP. 16: Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022

Surbhi Sidana, MD;Larry Anderson, MD;Caitlin Costello, MD;Andrew J. Cowan, MD;Rebecca Silbermann, MD
November 2nd 2022

Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

EP. 17: Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff
November 5th 2022

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.